ArticleJCO oncology practice2021

Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.

Edward Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.